Aarhus University (AU)
This sponsor has funded 2 studies across 1 countries.
| EU PAS ID | Status | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|
| 34887 | Finalised | Renin-angiotensin-aldosterone system inhibitors and adverse outcomes of COVID-19: a Danish nationwide cohort study (ACE-I/ARB and COVID-19) | Yes | No |
| 37790 | Ongoing | The effect of mental disorders and treatment with psychotropic agents on the course of COVID-19 (COVID-19 psychotropics) | Yes | No |
PAS by Risk Management Plan (RMP) requirement
Aarhus University (AU)
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Aarhus University (AU)
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Aarhus University (AU)
1 Study countries specified are the following:
- Denmark